Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Capital Expenditures (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Capital Expenditures data on record, last reported at $387000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures rose 3418.18% year-over-year to $387000.0; the TTM value through Sep 2025 reached $630000.0, up 162.5%, while the annual FY2024 figure was $203000.0, 87.44% down from the prior year.
  • Capital Expenditures reached $387000.0 in Q3 2025 per STOK's latest filing, up from -$101000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.2 million in Q2 2022 and bottomed at -$1.1 million in Q3 2022.
  • Average Capital Expenditures over 4 years is $158533.3, with a median of $192000.0 recorded in 2024.
  • The widest YoY moves for Capital Expenditures: up 3418.18% in 2025, down 1583.33% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at -$285000.0 in 2022, then skyrocketed by 180.35% to $229000.0 in 2023, then dropped by 16.16% to $192000.0 in 2024, then surged by 101.56% to $387000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $387000.0 in Q3 2025, -$101000.0 in Q2 2025, and $152000.0 in Q1 2025.